| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Tumor cell growth is irreversibly reduced and morphological alterations are induced by C8-ceramide (3 μM; 48 hours) [1]. In human cervical carcinoma cells, C8-ceramide can cause necrosis-like cell death, but it does not cause the molecular marker of apoptosis, PARP, to be cleaved in a caspase-dependent manner [1]. In NSCLC H1299 cells, C8-ceramide may elevate endogenous ROS levels (10-30 µM; 24 hours), inhibit proliferation (10-50 µM; 24 hours), and therefore induce apoptosis (10-50 µM; 48 hours) [2].
|
|---|---|
| ln Vivo |
In mice infected with a virus, C8-ceramide (0.1 mg/kg; administered intravenously) increases CD8+ and CD4+ T cell responses to infection [3].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: CALO cells, INBL cells, HeLa cells Tested Concentrations: 3 μM Incubation Duration: 48 hrs (hours) Experimental Results: The number of tumor cells was Dramatically diminished. Cell proliferation assay[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM, 40 µM, 50 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished cell proliferation rate in a dose-dependent manner, IC50 22.9 µM. Cell cycle analysis[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM, 40 µM, 50 µM Incubation Duration: 24 hrs (hours) Experimental Results: Causes G1 arrest. Apoptosis analysis[2] Cell Types: H1299 Cell Tested Concentrations: 10 µM, 20 µM, 30 µM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Increased levels of cleaved caspase-3. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice, lymphocytic choriomeningitis virus infection [3]
Doses: 0.1 mg/kg Route of Administration: Intranasal administration Experimental Results: Enhanced lung CD8+ T cell response to influenza. |
| References |
|
| Additional Infomation |
N-octanoylsphingosine is an N-acylsphingosine in which the ceramide N-acyl group is specified as octanoyl. It is functionally related to an octanoic acid.
|
| Molecular Formula |
C26H51NO3
|
|---|---|
| Molecular Weight |
425.69
|
| Exact Mass |
425.386
|
| CAS # |
74713-59-0
|
| PubChem CID |
5702614
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
595.5±50.0 °C at 760 mmHg
|
| Melting Point |
68-70°C
|
| Flash Point |
313.9±30.1 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.482
|
| LogP |
9.09
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
30
|
| Complexity |
398
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCC/C=C/[C@H]([C@H](CO)NC(=O)CCCCCCC)O
|
| InChi Key |
APDLCSPGWPLYEQ-WRBRXSDHSA-N
|
| InChi Code |
InChI=1S/C26H51NO3/c1-3-5-7-9-10-11-12-13-14-15-16-18-19-21-25(29)24(23-28)27-26(30)22-20-17-8-6-4-2/h19,21,24-25,28-29H,3-18,20,22-23H2,1-2H3,(H,27,30)/b21-19+/t24-,25+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]octanamide
|
| Synonyms |
N-Octanoyl-D-erythro-Sphingosine; C8-Ceramide; C8 Ceramide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~234.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3491 mL | 11.7456 mL | 23.4913 mL | |
| 5 mM | 0.4698 mL | 2.3491 mL | 4.6983 mL | |
| 10 mM | 0.2349 mL | 1.1746 mL | 2.3491 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
